Site Overlay

Treatment with SGLT-2 inhibitors and urinary tract and genital infections risk

Volume 10, Issue 2

Original Article / Published: November 2022


D. Petrova

Department of Urology and Nephrology
Military Medical Academy, Sofia, Bulgaria


The kidneys are involved in the regulation of glucose homeostasis by reabsorbing glucose filtered into the glomerular filtrate. Reabsorption occurs in the proximal convoluted tubule and is carried out by two isoforms of the sodium-glucose cotransporters (SGLTs). SGLT-2 inhibitors suppress renal glucose reabsorption by lowering the renal threshold for glucose excretion by inhibiting SGLT-2 protein in the proximal tubule of the kidney. As a result, the excretion of glucose in the urine increases. SGLT-2 inhibitors have revolutionized the treatment of patients with type 2 diabetes mellitus with or without cardiovascular disease and patients with diabetic nephropathy. The mechanism of action, SGLT-2 inhibitors is associated with an increase in glycosuria, a risk factor for genital and urinary infections. Additional studies and monitoring of adverse side effects and complications of treatment with these medications are needed. The occurrence of mild to moderate genital and urinary tract infections can be treated according to good clinical practice guidelines for this type of disease, and the continuation of treatment should be determined individually for each patient.



  1. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001 Feb;24(2):382-91. doi: 10.2337/diacare.24.2.382.
  2. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011 Mar;(120):S1-6. doi: 10.1038/ki.2010.509.
  3. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011 Apr;91(2):733-94. doi: 10.1152/physrev.00055.2009.
  4. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010 Feb;27(2):136-42. doi: 10.1111/j.1464-5491.2009.02894.x.
  5. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012 Jan;14(1):5-14. doi: 10.1111/j.1463-1326.2011.01511.x.
  6. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951 Feb;30(2):125-9. doi: 10.1172/JCI102424.
  7. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al.; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389.
  8. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al.; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925.
  9. Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney Int Rep. 2022 May 5;7(7):1463-1476. doi: 10.1016/j.ekir.2022.04.094.
  10. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303.
  11. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816.
  12. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al.; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744.
  13. Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Adv Ther. 2022 Jan;39(1):148-164. doi: 10.1007/s12325-021-01994-2.
  14. Chronic Kidney Disease in the United States, March 04, 2021. Centers for disease control and prevention. Available at: Accessed 10 Dec 2022
  15. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017 Apr;3(1):7-11. doi: 10.15420/cfr.2016:25:2.
  16. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014 Mar;103(3):373-81. doi: 10.1016/j.diabres.2013.12.052.
  17. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about serious urinary tract infections. 3-19-2020 Update; Revised 3-15-2022. Available at: Accessed 10 Dec 2022
  18. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes, 8-29-2018. Available at: Accessed 10 Dec 2022
  19. Nelinson DS, Sosa JM, Chilton RJ. SGLT2 inhibitors: a narrative review of efficacy and safety. J Osteopath Med. 2021 Feb 1;121(2):229-239. doi: 10.1515/jom-2020-0153.
  20. Hirji I, Guo Z, Andersson SW, Hammar N, Gomez-Caminero A. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complications. 2012 Nov-Dec;26(6):513-6. doi: 10.1016/j.jdiacomp.2012.06.008.
  21. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014 Jun;104(3):297-322. doi: 10.1016/j.diabres.2014.02.014.
  22. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014 Sep 11;8:1335-80. doi: 10.2147/DDDT.S50773.
  23. Gadzhanova S, Pratt N, Roughead E. Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program. Diabetes Res Clin Pract. 2017 Aug;130:180-185. doi: 10.1016/j.diabres.2017.06.018.
  24. Liu J, Li L, Li S, Jia P, Deng K, Chen W, Sun X. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017 Jun 6;7(1):2824. doi: 10.1038/s41598-017-02733-w.
  25. Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019 Feb;21(2):434-438. doi: 10.1111/dom.13531.
  26. Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Ann Intern Med. 2019 Aug 20;171(4):248-256. doi: 10.7326/M18-3136.
  27. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013 Sep-Oct;27(5):479-84. doi: 10.1016/j.jdiacomp.2013.04.012.
  28. Kushner P. Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes. Womens Health (Lond). 2016 Jun;12(3):379-88. doi: 10.2217/whe-2016-0001.
  29. Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018 Oct;61(10):2118-2125. doi: 10.1007/s00125-018-4663-6.
Volume 10, Issue 2


SGLT-2 inhibitors, glycosuria, urinary tract infections

How to cite this article:

Petrova D. Treatment with SGLT-2 inhibitors and urinary tract and genital infections risk. Journal of Endourology and Minimally Invasive Surgery (Bulgaria), 2022; 10(2):5-9

Corresponding author:

Dr. Daniela Petrova, MD, PhD

Military Medical Academy of Sofia
Department of Urology and Nephrology
3 “Georgi Sofiiski” blvd.
Sofia 1606, Bulgaria